When was Lisata founded?

Lisata was founded in 2006 and raised its 1st funding round 3 years after it was founded.

Where is Lisata located?

Lisata is headquartered in Basking Ridge, United States.

How many employees does Lisata have?

As of Jan 31, 2026, the latest employee count at Lisata is 38.

Is Lisata a funded company?

Lisata is a funded company, having raised a total of $6.58M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 30, 2009.

When was the latest funding round of Lisata?

Lisata's latest funding was a $***** Seed round on Jul 15, 2020, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.37B in funding in 2026 to date.

Where does Lisata rank among its competitors?

Lisata ranks 330th amongst 3564 active competitors, of which 1214 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Lisata?

Lisata's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Lisata - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapeutics for cancer and vascular disorders. It offers a CendR Platform that provides tumor-targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. It also offers an autologous CD34+ cell therapy platform for diseases and conditions caused by ischemia.

Website: www.lisata.com/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2006

Location

Basking Ridge, United States

Stage

Acquired

Total Funding

$6.58M in 13 rounds

Latest Funding Round

Seed, Jul 15, 2020, $*****

Investors

Military Health & 2 more

Ranked

330^th among 3564 active competitors

Employee Count

38 as on Jan 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3326 more

Exit Details

Acquired by Kuva Labs (Jan 21, 2026)

View Lisata's full profile

Lisata is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FRESH TRACKS THERAPEUTICS, INC. CIN: 819050 , United States, Active	Apr 29, 1987	$8.01M (As on Dec 31, 2023)	13 (As on Dec 31, 2022)	-
Lisata Therapeutics, Inc. CIN: 222343568 , United States, Active	Dec 31, 1999	$1M (As on Dec 31, 2024)	25 (As on Dec 31, 2024)	-
LISATA THERAPEUTICS (UK) LIMITED CIN: SC424469 , United Kingdom, Active	May 17, 2012	-	-
LISATA THERAPEUTICS, INC. CIN: 2875139 , United States, Active	Feb 27, 2003	-	-	-

Lisata got acquired by Kuva Labs on Jan 21, 2026. It was facilitated by Mintz, H.C. Wainwright and Goodwin.

Click here to take a look at Lisata's acquisition in detail

Lisata has raised a total funding of $6.58M over 13 rounds. Its first funding round was on Sep 30, 2009. Lisata has 3 institutional investors.

Here is the list of recent funding rounds of Lisata:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2020	2928858	Seed	5414595	2764522	9797098	7578410
May 28, 2020	6991308	Seed	1799402	1743412	6432711	9588042
Apr 27, 2020	2634395	Seed	8116363	5559422	8609381	9279805

Access funding benchmarks and valuations. Sign up today!

View details of Lisata's funding rounds and investors

Lisata's employee count trend

Lisata has 38 employees as of Jan 26. Here is Lisata's employee count trend over the years:

Uncover Lisata's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lisata include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Lisata, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
9th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
330th	Lisata 2006, Basking Ridge (United States), Acquired	Developer of therapeutics for cancer and vascular disorders	$6.58M	Military Health, HHS & 1 others	58/100